Global Diagnostic Radiopharmaceuticals Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global Diagnostic Radiopharmaceuticals Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Diagnostic Radiopharmaceuticals market size was valued at US$ 5196 million in 2024 and is forecast to a readjusted size of USD 8217 million by 2031 with a CAGR of 6.7% during review period.

Radiopharmaceuticals refer to a special class of drugs containing radionuclides for medical diagnosis and treatment. Compounds or biological agents labeled with radionuclides used for medical diagnosis or treatment in the body.

Diagnostic radiopharmaceuticals are radioactive isotopes bound to biological molecules that can locate specific organs, tissues or cells in the human body. These radiopharmaceuticals can be used to diagnose diseases.

In vivo radiopharmaceuticals can be divided into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, and the main diseases targeted include thyroid diseases, tumors, rheumatoid arthritis, bone metastasis, liver cancer, etc.

The diagnostic radiopharmaceuticals market is primarily driven by the rising incidence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions, which require advanced imaging techniques for accurate diagnosis. The increasing use of PET and SPECT scans in healthcare systems worldwide has significantly boosted demand for diagnostic radiopharmaceuticals. Furthermore, innovations in molecular imaging, along with a growing focus on early detection and personalized medicine, are expanding the role of diagnostic radiopharmaceuticals in improving patient outcomes.

One of the key challenges facing the diagnostic radiopharmaceuticals market is the short half-life of many radiopharmaceutical compounds, which creates logistical difficulties in production, transportation, and storage. This limitation often requires proximity to specialized manufacturing facilities. Additionally, the market is constrained by regulatory barriers and the high costs associated with development and approval. Another challenge is the shortage of trained professionals in nuclear medicine, which limits the full utilization of diagnostic radiopharmaceuticals, particularly in emerging economies.

North America is the world's major consumer region, with sales accounting for 40% of the global total in 2023. Europe is also a major consumer region, accounting for 25% of the global market. China is also a very important consumer region due to the large number of cancers. At present, products represented by Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Pharma, Bracco Imaging, etc. occupy a major position in the global market.

This report is a detailed and comprehensive analysis for global Diagnostic Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Diagnostic Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Diagnostic Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Diagnostic Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2020-2031

Global Diagnostic Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Diagnostic Radiopharmaceuticals

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Diagnostic Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Eli Lilly, China Isotope & Radiation, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Diagnostic Radiopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Technetium 99
Fluorine 18
Other

Market segment by Application
Oncology
Cardiology
Other

Major players covered
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Eli Lilly
China Isotope & Radiation
Dongcheng

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Diagnostic Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Diagnostic Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of Diagnostic Radiopharmaceuticals from 2020 to 2025.

Chapter 3, the Diagnostic Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Diagnostic Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Diagnostic Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Diagnostic Radiopharmaceuticals.

Chapter 14 and 15, to describe Diagnostic Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.